Strides and Apotex to merge Australian generics businesses

Home/Pharma News | Posted 22/06/2018 post-comment0 Post your comment

India-based generics manufacturer Strides Shasun (Strides) announced on 9 May 2018 that it had made an agreement with Canada-based Apotex to merge their Australian businesses.

104 MD001918

Strides, under the Arrow brand, is one of the leading generics makers in the Australian pharmaceutical market. Apotex is the leading generics maker in this market. The two companies have agreed in principle to merge their Australian generics businesses under a new entity, although this will exclude Apotex’s hospital business.

The combination, according to Strides, will enable it to become the leading player in the Australian generics market by both volume and revenue. The merged business will have the largest portfolio generics and approx. 3,200 first-line pharmacy accounts for the Australian market. The merged business will be supported by manufacturing facilities from both Strides and Apotex.

The combined Strides and Apotex business will be run independently under the Arrow and Apotex brands, respectively, and continue to enjoy preferred partner relationship with their respective wholesalers.

According to Mr Roger Millichamp, CEO of Apotex Australia, although both companies are currently in a strong commercial position, the merger will mean that they ‘will be better positioned to meet the future challenges of the Australian pharmaceutical industry’. 

This is not the first time Strides has expanded its Australian business. In February 2016, the company signed a deal to acquire a strategic stake in Generic Partners Holdings, an Australian pharmaceutical supply and research company [1].

Related articles
Australia’s TGA publishes protocol to address drug shortages

Australians pay too much for prescription drugs

1.  GaBI Online - Generics and Biosimilars Initiative. Australians pay too much for generics []. Mol, Belgium: Pro Pharma Communications International; [cited 2018 Jun 22]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2018 Pro Pharma Communications International. All Rights Reserved.

Source: Strides

comment icon Comments (0)
Post your comment
Related content
GaBI news digest for 14 October 2022
56 AA011042
Home/Pharma News Posted 14/10/2022
Novartis is set to spin-off Sandoz
Guidance V13F21
Home/Pharma News Posted 16/09/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010